Author:
Azam Mohammed Ali,Chakraborty Praloy,Si Daoyuan,Du BeiBei,Massé Stéphane,Lai Patrick F.H.,Ha Andrew C.T.,Nanthakumar Kumaraswamy
Funder
Canadian Institutes of Health Research
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference56 articles.
1. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects;Lam;J. Am. Heart Assoc.,2019
2. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N. Engl. J. Med.,2019
3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N. Engl. J. Med.,2017
4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N. Engl. J. Med.,2019
5. Yurista SR, Sillje HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail.. 2019;21(7):862–73.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献